NCT01477411View on ClinicalTrials.gov

A Drug-Drug Interaction Study of Digoxin and PA21

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Drug Interaction Potentiation

Interventions

DRUG

PA21

The maximum dose of PA21 will be 15.0 g/day.

DRUG

Digoxin

The maximum dosage of Digoxin will be 0.5 mg/day

Trial Locations (1)

92801

ACRI - Phase 1, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Vifor Pharma

INDUSTRY